Per Reuters
Biogen Stock Surged 35.4% After Success of Experimental Alzheimer's Drug
9/28/2022
The success of Biogen's experimental Alzheimer's drug with Eisai resulted in the company's stock surging by 35.4%. Eisai's stock also rose by 17% to Tokyo's daily limit.
After the news, even shares of its rivals Eli Lilly and Roche increased by 6% and 7%. Smaller Alzheimer's drug developers Prothena Corporation Plc and Acumen Pharmaceuticals Inc rose by 64% and 61% respectively.
See full $BIIB flow at unusualwhales.com/flow.
+With Unusual Whales
Get the best broker for options trading and earn Unusual Whales discounted! in cash with an eligible account deposit at tastytrade. Get an Unusual Whales bonus when you deposit $2000. Offer expires 3/31/25. Certain restrictions, terms and conditions apply.